Cecilia Linde Karolinska University Hospital Stockholm

Size: px
Start display at page:

Download "Cecilia Linde Karolinska University Hospital Stockholm"

Transcription

1 The mildly symptomatic patient with low EF, moderate/severe mitral regurgitation and QRS 140 ms Cecilia Linde Karolinska University Hospital Stockholm

2 Presenter Disclosure Information Cecilia Linde, MD, PhD The following relationships exist related to this presentation: Consulting Fees, Medtronic and St. Jude Research Grants, Medtronic and the Sweden Heart and Lung Foundation

3 Importance of mitral regurgitation in heart failure Functional mitral regurgitation Consequence of LV systolic dysfunction Or a direct result of dyssynchrony Valvular mitral regurgitation Also responsible for HF progression Mod/sev MR aggravates symptoms and is linked to adverse outcome

4 Mitral regurgitation Absent/Minimal = 0 Mild = 1 Moderate = 2 Mod/sev = 3 Severe = 4

5 The case NYHA I/II, MR, low LVEF, QRS 140 ms Drug refractory Mild Symptoms NYHA II HF low LVEF + Electrical dyssynchrony QRS 140 ms + Mitral regurg CRT + 60% Guidelines offer no recommendation for Mitral regurgitation Will this patient improve?

6 Mitral regurgitation in RCT of CRT in patients NYHA III/IV

7 Mustic Study Mod/severe MR in NYHA III HF pts in RCTs for CRT MUSTIC Baseline: NYHA III, LVEF 22%, QRS 172 ms, MR cm 2 Mod/Severe MR common and significantly reduced by CRT (12 months) It was an on/off phenomenon and came back in inactive crossover phase Duncan et al Eur Heart J 2003

8 ms cm2 % mm mm Mustic Study MR jet area BASELINE MUSTIC 1-year Follow-up NYHA III QRS > 150 ms, LVEDD> 60 mm LVEDD BASELINE cm 2 M12 p <0.01 M12 LVEF (radionuclides) p < % BASELINE cm 2 M12 p < LVESD BASELINE DFT BASELINE M12 M12 p <0.01 (Linde et al JACC 2002;40:111) p <0.01

9 Mean difference in mitral regurgitation index (u) 0 MR index index (u) over time in the CARE-HF study NYHA III/IV LVEF 25%, QRS 160 ms, MR index 0.21 % MR index= Area of jet/ area of LA in systole Ghio S et al. Eur J Heart Fail 2009;11: months 9 months 18 months 29 months P< P= P=0.004 P=0.015 CRT significantly reduced MR index already at discharge with maintained effect of 4 U p= over time

10 Mitral regurgitation in RCT of CRT in patients with mild heart failure NYHA II/I

11 REVERSE and MADIT-CRTCRT in NYHA II/I Reduction in heart failure related hospitalizations REVERSE: Time to first heart failure hospitalization in the first 12 months (secondary end point) MADIT-CRT: Kaplan-Meier estimate of heart-failure free survival probability (part of primary end point) 2.4 years - 53 % relative risk reduction - 41 % relative risk reduction C. Linde et al., JACC 2008; 52: Moss, AJ, et al., NEJM ;1329)

12 Powered Secondary End Point: LVESVi over 24 months 110 LVESVi (ml/m 2 ) ,6 93,9 92,5 76,8 CRT OFF 91,6 CRT ON 88,8 94,5 P< ,6 69,2 69, Months Since Randomization Progressive P-value reverse compares remodeling 24-month by changes. CRT evolved over 18 months in REVERSE Daubert et al JACC 2009;54:1837

13 Moderate/severe MR in REVERSE LVEF 26%, QRS 154 ms, MR 15 % (jet in LA) = mild MR was found in minority of pts, was mild and was not significantly affected by CRT (12 months) St John Sutton M et al Circulation 2009;120:1858

14 Mod/sev MR in in MADIT-CRT LVEF 24.6%, QRS 159 ms, MR cm Solomon et al Cir 2010;122:985 Most often mild MR P=0.02 In MADIT CRT MR was mild and most often did not change by CRT MR improvement > 1 point more often in CRT vs control p=0.02 Mitral jet width (m=88) significantly reduced in CRT p<0.0003

15 Observational studies

16 Verhaert D et al Circ Cardiovasc Imaging 2012;5:21 Estimated time course of MR severity in CRT treated pts N=266, NYHA II-IV LVEF 25%, QRS 162 ms MR measured as Vena contracta (VC) witdh Decrease in MR was immediate day 3 and was maintained at same magnitude over follow up of 3.6 years

17 Time course of reverse remodeling LVESVi MR measured as Vena contracta (VC) witdh Early Long term Longer term reduction in MR is correlated to decrease in LVESVi Verhaert D et al Circ Cardiovasc Imaging 2012;5:21

18 Event-free survival in pt +/- mod/sev residual MR after 6 months CRT In 266 pts most in NYHA III, 40% had MR > 2 at baseline Pts with less mod/severe residual MR after 6 months of CRT had better survival Verhaert D et al Circ Cardiovasc Imaging 2012;5:21

19 Di Biase L et al Europace 2011;13:829 Impact of CRT on severity of MR 794 pt treated with CRT from 4 registries Mitral regurgitation present in 86% Mod/severe MR grade 3-4 in 35% Improvements of MR > 1 after 12 months in 46% In those with mod/severe MR grade % p< 0.01 improved (Improvement = NYHA > 1 and LVEF > 5%)

20 Baseline and 3 months MR severity in 794 pt treated with CRT from 4 registries followed for 12 months Di Biase L et al Europace 2011;13:829 More advanced MR at baseline and reduction in MR after 3 months were predictors of response (NYHA > 1 and LVEF > 5%)

21 Conclusions Mitral regurgitation in NYHA III/IV CRT candidates Moderate severe mitral regurgitation is present in 35% of CRT candidates pts more symptomatic and more dilated ventricles CRT reduces MR, reverses remodeling and improves symptoms and prognosis in these pts

22 Conclusions Mitral regurgitation in NYHA I/II CRT candidates Mitral regurgitation is found in 15% of CRT candidates mild NYHA I/II and is mostly mild as evidenced from RCT (REVERSE, MADIT-CRT) Most commonly MR is unaffected by CRT But in MADIT-CRT MR was somewhat reduced by CRT but evidence is less clear

23 Conclusions Mitral regurgitation in NYHA III/IV CRT candidates Reduction of mitral regurgitation is immediate and linked to reverse remodeling MR at baseline in some studies predicts response to CRT but Early reduction of MR is a predictor of response to CRT And linked to better survival

24 The case NYHA I/II, mod/sev MR, low LVEF QRS 140 ms Drug refractory Mild Symptoms NYHA II HF LVEF low + Electrical dyssynchrony QRS 140 ms QRS > 120 ms + Mitral regurg CRT + 60% Guidelines offer no recommendation for Mitral regurgitation This pt is rare but will probably improve

BENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT

BENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT BENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT Ilan Goldenberg MD Professor of Cardiology Sheba Medical Center and Tel Aviv University, Israel University of Rochester

More information

Is QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients?

Is QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients? Is QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients? Data from REVERSE C Thébault 1, M Gold 2, C Linde 3, WT Abraham 4, C Leclercq 1,

More information

Bi-Ventricular pacing after the most recent studies

Bi-Ventricular pacing after the most recent studies Seminars of the Hellenic Working Groups February 18th-20 20,, 2010, Thessaloniki, Greece Bi-Ventricular pacing after the most recent studies Maurizio Lunati MD Director EP Lab & Unit Cardiology Dpt. Niguarda

More information

DECLARATION OF CONFLICT OF INTEREST. None to declare

DECLARATION OF CONFLICT OF INTEREST. None to declare DECLARATION OF CONFLICT OF INTEREST None to declare Influence of left and right ventricular leadtip position on clinical outcome after CRT: results from REVERSE C Thébault 1, C Meunier 1, R Gervais 1,

More information

Left Ventricular Ejection Fraction >35%

Left Ventricular Ejection Fraction >35% Controversies in Cardiac Resynchronisation Therapy Left Ventricular Ejection Fraction >35% Professor John GF Cleland University of Hull Kingston-upon-Hull United Kingdom Conflict of Interest: I have received

More information

I NON RESPONDERS ALLA CRT: UN PROBLEMA DI NON SEMPLICE SOLUZIONE

I NON RESPONDERS ALLA CRT: UN PROBLEMA DI NON SEMPLICE SOLUZIONE I NON RESPONDERS ALLA CRT: UN PROBLEMA DI NON SEMPLICE SOLUZIONE Gaetano Senatore S.C. CARDIOLOGIA OSPEDALE DI CIRIE & OSPEDALE DI IVREA LABORATORIO di Today s Patient Selection for CRT +AF and PM patients

More information

Imaging in dilated cardiomyopathy : factors associated with a poor outcome

Imaging in dilated cardiomyopathy : factors associated with a poor outcome Imaging in dilated cardiomyopathy : factors associated with a poor outcome Johan De Sutter, MD, PhD, FESC AZ Maria Middelares Gent and University Gent - Belgium Dilated cardiomyopathy Cardiomyopathy with

More information

The Role of ICD Therapy in Cardiac Resynchronization

The Role of ICD Therapy in Cardiac Resynchronization The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine

More information

Effect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin

Effect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin Effect of Ventricular Pacing on Myocardial Function Inha University Hospital Sung-Hee Shin Contents 1. The effect of right ventricular apical pacing 2. Strategies for physiologically optimal ventricular

More information

Device therapy in heartfailure Update of the ESC guidelines. Karl Swedberg

Device therapy in heartfailure Update of the ESC guidelines. Karl Swedberg Device therapy in heartfailure Update of the ESC guidelines Karl Swedberg Professor of Medicine Department of emergency and cardiovascular medicine Sahlgrenska Academy University of Gothenburg, Sweden

More information

Functional Mitral Regurgitation

Functional Mitral Regurgitation Club 35 - The best in heart valve disease - Functional Mitral Regurgitation Steven Droogmans, MD, PhD UZ Brussel, Jette, Belgium 08-12-2011 Euroecho & other Imaging Modalities 2011 No conflicts of interest

More information

BSH Annual Autumn Meeting 2017

BSH Annual Autumn Meeting 2017 BSH Annual Autumn Meeting 2017 Presentation title: The Development of CRT Speaker: John GF Cleland Conflicts of interest: I have received research support and honoraria from Biotronik, Boston Scientific,

More information

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital

More information

Implantable cardioverter-defibrillators and cardiac resynchronization therapy

Implantable cardioverter-defibrillators and cardiac resynchronization therapy Implantable cardioverter-defibrillators and cardiac resynchronization therapy Johannes Holzmeister, MD University Hospital Zurich, Zurich, Switzerland Frontiers of heart failure controversies, ESC - Paris

More information

Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx

Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx Charles Gottlieb, MD Director of Electrophysiology Abington Memorial Hospital Heart Failure Mortality Mechanism of death

More information

Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure

Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart

More information

CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT?

CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT? CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT? Alessandro Lipari, MD Chair and Department of Cardiology University of Study and Spedali Civili Brescia -Italy The birth of CRT in Europe, 20 years ago

More information

How do I convert my CRT Non Responder into Responder?

How do I convert my CRT Non Responder into Responder? How do I convert my CRT Non Responder into Responder? Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting Boston Scientific, Medtronic

More information

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Matteo Anselmino Division of Cardiology Città della Salute e della Scienza Hospital University of Turin, Italy Disclosure: Honoraria

More information

CRT in the RV Paced Patient When to Upgrade?

CRT in the RV Paced Patient When to Upgrade? Ben Gurion University CRT in the RV Paced Patient When to Upgrade? I. Eli Ovsyshcher, MD, PhD, FESC, FACC, FHRS, FA Professor of Medicine/Cardiology Ben Gurion University of the Negev Beer-Sheva, Israel

More information

IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE

IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRS Cardiology San Francisco General Hospital UCSF Disclosures: None LEADING CAUSES OF DEATH IN US Sudden cardiac

More information

Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.

Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J. Saving Lives and Preventing Heart Failure: The MADIT Family of Trials Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Update in Electrocardiography

More information

Devices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine

Devices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football

More information

This is What I do to Improve CRT Response for CRT Non-Responders

This is What I do to Improve CRT Response for CRT Non-Responders This is What I do to Improve CRT Response for CRT Non-Responders Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Steering Committees (unpaid) and Clinical Trials,

More information

CRT: whom does it benefit?

CRT: whom does it benefit? CRT: whom does it benefit? Francisco Leyva BSH Revalidation and Training 2018 Queen Elizabeth Hospital NICE guidelines for CRT LVEF 35% NYHA class I II III IV QRS

More information

Guidelines in perspective?

Guidelines in perspective? EuroValve 2016 Challenges in the management Secondary MR Guidelines in perspective? Luc A. Pierard, MD, PhD Professor of Medicine Head of the Department of Cardiology, Liège, Belgium Heart Valve Clinic,

More information

Cardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing

Cardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing Cardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing Philippe Mabo University Hospital, Rennes, France ESC Congress 2010, Stockholm 29 Aug 2010 Which Patients? Candidate for

More information

Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure

Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure Edmund Keung, MD Clinical Chief, Cardiology Section San Francisco VAMC October 25, 2008 Presentation Outline

More information

PARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR

PARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR PARAVALVULAR LEAK POST TAVR David S Rubenson MD FACC FASE Founding Director, Cardiac Non-Invasive Laboratory Scripps Clinic Medical Group number 1 Elements of Follow-up Post TAVR JACC CV Imag 2016;9:193

More information

Treatment options in ischaemic mitral regurgitation: surgery, clips, devices?

Treatment options in ischaemic mitral regurgitation: surgery, clips, devices? Treatment options in ischaemic mitral regurgitation: surgery, clips, devices? Francisco Leyva Conflicts of interest: FL has received advisory board fees from Medtronic Inc, Sorin, St Jude Medical and Abbot.

More information

Primary Mitral Regurgitation

Primary Mitral Regurgitation EURO VALVE Madrid News from Valves Guidelines 2012: What s new and Why? Primary Mitral Regurgitation Luc A. Pierard, MD, PhD Professor of Medicine Head of the Department of Cardiology Heart Valve Clinic,

More information

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Severe left ventricular dysfunction and valvular heart disease: should we operate? Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016 Disclosure : No conflict

More information

Journal of the American College of Cardiology Vol. 52, No. 23, by the American College of Cardiology Foundation ISSN /08/$34.

Journal of the American College of Cardiology Vol. 52, No. 23, by the American College of Cardiology Foundation ISSN /08/$34. Journal of the American College of Cardiology Vol. 52, No. 23, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.027

More information

Should ICD Replacement Be Performed in Octogenarians and/or Severe Comorbidities?

Should ICD Replacement Be Performed in Octogenarians and/or Severe Comorbidities? Should ICD Replacement Be Performed in Octogenarians and/or Severe Comorbidities? JC Daubert Rennes, France Disclosure 2008-2011 Medical devices Speaker Consultant Trial committees EBR + + Impulse Dynamics

More information

Multisite Left Ventricular Pacing for Cardiac Resynchronization

Multisite Left Ventricular Pacing for Cardiac Resynchronization Multisite Left Ventricular Pacing for Cardiac Resynchronization C. W. Israel, M.D. Ass. Prof. Dept. of Medicine Cardiology Evangelical Hospital Bielefeld Germany J. W. Goethe University Frankfurt C.W.Israel@em.uni-frankfurt.de

More information

How atrial fibrillation should be treated in the heart failure patient?

How atrial fibrillation should be treated in the heart failure patient? Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 13/15 Ottobre 2016 How atrial fibrillation should be treated in the heart failure patient? Matteo Anselmino Dipartimento Scienze

More information

Importance of CRT team for optimization of the results: a European point of view

Importance of CRT team for optimization of the results: a European point of view Importance of CRT team for optimization of the results: a European point of view Matteo Bertini, MD, PhD Arcispedale S. Anna Azienda Ospedaliero-Universitaria Cona-Ferrara No conflict of interest to declare

More information

CRT-P or CRT-D From North Alberta to Nairobi

CRT-P or CRT-D From North Alberta to Nairobi CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:

More information

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS

More information

Cardiac Resynchronization Therapy for Heart Failure

Cardiac Resynchronization Therapy for Heart Failure Cardiac Resynchronization Therapy for Heart Failure Ventricular Dyssynchrony vs Resynchronization Ventricular Dysynchrony Ventricular Dysynchrony 1 Electrical: Inter- or Intraventricular conduction delays

More information

Large RCT s of CRT 2002 to present

Large RCT s of CRT 2002 to present Have We Expanded Our Use of CRT for Heart Failure Patients? Sana M. Al-Khatib, MD, MHS Associate Professor of Medicine Electrophysiology Section- Division of Cardiology Duke University Potential Conflicts

More information

Cardiac resynchronisation therapy (biventricular pacing) for the treatment of heart failure

Cardiac resynchronisation therapy (biventricular pacing) for the treatment of heart failure NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal for the treatment of heart failure Final scope Appraisal objective To appraise the clinical and cost effectiveness of cardiac

More information

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection

More information

Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy

Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic

More information

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,

More information

HF and CRT: CRT-P versus CRT-D

HF and CRT: CRT-P versus CRT-D HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA

More information

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech Disclosures ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech Speaker s fee Edwards Lifesciences Sanofi-Aventis Decision Making in Patients with Multivalvular

More information

Cardiac Resynchronization Therapy Guidelines and Missing Groups

Cardiac Resynchronization Therapy Guidelines and Missing Groups Cardiac Resynchronization Therapy Guidelines and Missing Groups Frank Pelosi, Jr., MD, FACC, FHRS Director, Cardiac Electrophysiology Fellowship Associate Professor of Medicine University of Michigan Health

More information

Follow-up of CRT patients ESC Munich Clinical and biological follow-up of CRT patients

Follow-up of CRT patients ESC Munich Clinical and biological follow-up of CRT patients Follow-up of CRT patients ESC Munich 12-08-26 Clinical and biological follow-up of CRT patients Frieder Braunschweig MD PhD FESC Associate Professor of Cardiology Karolinska University Hospital Stockholm,

More information

La stimulation biventriculaire (Traitement par Resynchronisation Cardiaque) Indications et Résultats. Daniel Gras, DIU, Paris 2007

La stimulation biventriculaire (Traitement par Resynchronisation Cardiaque) Indications et Résultats. Daniel Gras, DIU, Paris 2007 La stimulation biventriculaire (Traitement par Resynchronisation Cardiaque) Indications et Résultats, DIU, Paris 2007 CRT: Results and indications Background Results of CRT Studies Today s classical CRT

More information

I have financial relationships to disclose Honoraria from: Edwards

I have financial relationships to disclose Honoraria from: Edwards I have financial relationships to disclose Honoraria from: Edwards Mitral Valve Annuloplasty in Ischemic Mitral regurgitation Jean François Avierinos Hôpital Timone Marseille August 28, 2012 Ischemic MR

More information

Cardiac Resynchronization Therapy. Michelle Khoo, MD

Cardiac Resynchronization Therapy. Michelle Khoo, MD Cardiac Resynchronization Therapy Michelle Khoo, MD 10.7.08 HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations SD in Competitive Athletes

More information

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC NATURAL HISTORY OF MITRAL REGURGITATION Abdallah El Sabbagh et al. JIMG 2018;11:628-643 TREATMENT OPTIONS SURGERY REPAIR REPLACEMENT PERCUTANEOUS INTERVENTIONS

More information

Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation

Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?

More information

Sliwa et al. JACC 2004;44:

Sliwa et al. JACC 2004;44: TREATMENT OF ADVANCED HEART FAILURE HEART DISEASE IN KENTUCKY Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac

More information

Heart failure and sudden death

Heart failure and sudden death Heart failure and sudden death What did we learn so far from important ICD- and CRT trials? Helmut U. Klein M.D. University of Rochester Medical Center Heart Research Follow up Program Arrhythmic substrate

More information

Valvular Regurgitation: Can We Do Better Than Colour Doppler?

Valvular Regurgitation: Can We Do Better Than Colour Doppler? Valvular Regurgitation: Can We Do Better Than Colour Doppler? A/Prof David Prior St Vincent s Hospital Melbourne Sports Cardiology Valvular Regurgitation Valve regurgitation volume loads the ventricles

More information

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,

More information

Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011

Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011 Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite

More information

EBR Systems, Inc. 686 W. Maude Ave., Suite 102 Sunnyvale, CA USA

EBR Systems, Inc. 686 W. Maude Ave., Suite 102 Sunnyvale, CA USA Over 200,000 patients worldwide are estimated to receive a CRT device each year. However, limitations prevent some patients from benefiting. CHALLENGING PROCEDURE 5% implanted patients fail to have coronary

More information

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response

More information

Secondary MR joint with the mitral academy. What is new in our understanding of this disease? Luc Pierard University Hospital, Liège

Secondary MR joint with the mitral academy. What is new in our understanding of this disease? Luc Pierard University Hospital, Liège Secondary MR joint with the mitral academy What is new in our understanding of this disease? Luc Pierard University Hospital, Liège Faculty disclosure Luc Pierard I have no financial relationships to disclose.

More information

How to assess ischaemic MR?

How to assess ischaemic MR? ESC 2012 How to assess ischaemic MR? Luc A. Pierard, MD, PhD, FESC, FACC Professor of Medicine Head, Department of Cardiology University Hospital Sart Tilman, Liège ESC 2012 No conflict of interest Luc

More information

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid Patient records 76 y.o. male Hypertension. Dyslipidemia. OPLD. Smoked in the past. Diabetes

More information

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT and Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac

More information

What echo measurements are key prior to MitraClip?

What echo measurements are key prior to MitraClip? APHP CHU Bichat - Claude Bernard What echo measurements are key prior to MitraClip? Eric Brochet,MD Cardiology Department Hopital Bichat Paris France No disclosure Conflict of interest Case 69 y.o man

More information

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Steven F Bolling Professor of Cardiac Surgery University of Michigan Optimal Treatment of Functional MR Steven F Bolling Professor of Cardiac Surgery University of Michigan Functional MR Functional MR in Ischemia Badhwar, Bolling, chapter in: Advances in Heart Failure,

More information

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII I, (Alec Vahanian) DO have a financial interest/arrangement or affiliation

More information

How to Use Echocardiography for. Cardiac Resynchronization Therapy WHY TRY TO IMPROVE PATIENT SELECTION FOR CRT? PROSPECT: CRT Response at 6 Months

How to Use Echocardiography for. Cardiac Resynchronization Therapy WHY TRY TO IMPROVE PATIENT SELECTION FOR CRT? PROSPECT: CRT Response at 6 Months 2/6/12 How to Use Echocardiography for Cardiac Resynchronization Therapy John Gorcsan, MD University of Pittsburgh, Pittsburgh, PA Disclosures: Research Grant Support: Biotronik, GE, Medtronic, St. Jude,

More information

Natural History and Echo Evaluation of Aortic Stenosis

Natural History and Echo Evaluation of Aortic Stenosis Natural History and Echo Evaluation of Aortic Stenosis Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM AORTIC STENOSIS First valvular disease

More information

Functional Mitral Regurgitation; therapeutic continuum overview. Michele Senni. Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII

Functional Mitral Regurgitation; therapeutic continuum overview. Michele Senni. Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII Functional Mitral Regurgitation; therapeutic continuum overview Michele Senni Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII Functional Mitral Regurgitation FMR is not the result

More information

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function:

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography

More information

Αμφικοιλιακή βηματοδότηση: LBBB ή ευρύ QRS;

Αμφικοιλιακή βηματοδότηση: LBBB ή ευρύ QRS; ΠΑΝΕΛΛΗΝΙΑ ΣΕΜΙΝΑΡΙΑ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ 2016 ΟΜΑΔΑ ΕΡΓΑΣΙΑΣ ΚΑΡΔΙΑΚΗΣ ΑΝΕΠΑΡΚΕΙΑΣ Στρογγυλό τραπέζι: Χρόνια Καρδιακή Ανεπάρκεια Αμφικοιλιακή βηματοδότηση: LBBB ή ευρύ QRS; Ξυδώνας Σωτήριος, MD, FESC Β Καρδιολογικό

More information

MADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD

MADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD MADIT Studies: CRT in the Non-LBBB Patient and Other Findings Arthur J. Moss, MD University of Rochester Medical Cntr. Rochester, NY 13 th Annual New Frontiers in Heart Failure Rx NYC, NY January 26, 2013

More information

ESC Stockholm Arrhythmias & pacing

ESC Stockholm Arrhythmias & pacing ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from

More information

The SEPTAL CRT study (NCT: )

The SEPTAL CRT study (NCT: ) Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators The SEPTAL CRT study (NCT: 00833352) Christophe

More information

Resynchronization/Defibrillation

Resynchronization/Defibrillation Resynchronization/Defibrillation for Ambulatory Heart Failure Trial Cardiac Resynchronization Therapy for Mild to Moderate Heart Failure George Wells University of Ottawa Heart Institute Department of

More information

Ενδείξεις αμφικοιλιακής βηματοδότησης. Ποιοι ασθενείς με καρδιακή ανεπάρκεια πρέπει να λάβουν αμφικοιλιακό απινιδωτή;

Ενδείξεις αμφικοιλιακής βηματοδότησης. Ποιοι ασθενείς με καρδιακή ανεπάρκεια πρέπει να λάβουν αμφικοιλιακό απινιδωτή; Ενδείξεις αμφικοιλιακής βηματοδότησης. Ποιοι ασθενείς με καρδιακή ανεπάρκεια πρέπει να λάβουν αμφικοιλιακό απινιδωτή; Άννα Κωστοπούλου Επιμελήτρια Α Ωνάσειο Καρδιοχειρουργικό Κέντρο Τμήμα Ηλεκτροφυσιολογίας

More information

Déclaration de Relations Professionnelles -Disclosure Statement of Financial Interest SPEAKER NAME. Nothing to disclose

Déclaration de Relations Professionnelles -Disclosure Statement of Financial Interest SPEAKER NAME. Nothing to disclose Déclaration de Relations Professionnelles -Disclosure Statement of Financial Interest SPEAKER NAME Nothing to disclose Resynchronisation en pédiatrie Paediatric resynchronisation J. Janoušek Kardiocentrum

More information

Imaging and heart failure

Imaging and heart failure Imaging and heart failure Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston, St Jude, BMS imaging, GE Healthcare,

More information

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC MitraClip Therapy Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Program Director, Interventional Cardiology Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

More information

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and 1 The clinical syndrome of heart failure in adults is commonly associated with the etiologies of ischemic and non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, hypertensive heart disease,

More information

Μη φαρμακευτική θεραπεία στην Χρόνια Καρδιακή Ανεπάρκεια Νεότερες συσκευές. Ξυδώνας Σωτήριος, MD, PhD, FESC

Μη φαρμακευτική θεραπεία στην Χρόνια Καρδιακή Ανεπάρκεια Νεότερες συσκευές. Ξυδώνας Σωτήριος, MD, PhD, FESC ΠΑΝΕΛΛΗΝΙΑ ΣΕΜΙΝΑΡΙΑ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ 2017 ΟΜΑΔΑ ΕΡΓΑΣΙΑΣ ΚΑΡΔΙΑΚΗΣ ΑΝΕΠΑΡΚΕΙΑΣ Μη φαρμακευτική θεραπεία στην Χρόνια Καρδιακή Ανεπάρκεια Νεότερες συσκευές Ξυδώνας Σωτήριος, MD, PhD, FESC Καρδιολογικό Τμήμα,

More information

When to ablate patients with premature ventricular complexes?

When to ablate patients with premature ventricular complexes? When to ablate patients with premature ventricular complexes? Nikolaos Fragakis Assistant Professor, FESC 3rd University Cardiology Department Hippokration Hospital, Thessaloniki 58 year-old female Case

More information

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/19036 holds various files of this Leiden University dissertation. Author: Bommel, Rutger Jan van Title: Cardiac resynchronization therapy : determinants

More information

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun Clinical Outcome of Tricuspid Regurgitation David Messika-Zeitoun I have financial relationships to disclose Consultant for: Edwards, Symetis and Valtech Tricuspid Regurgitation is a Common Finding Tricuspid

More information

Mitral valve treatment in advanced heart failure: Repair, Replacement, MitraClip. Nicola Buzzatti, MD San Raffaele Scientific Institute Milan, Italy

Mitral valve treatment in advanced heart failure: Repair, Replacement, MitraClip. Nicola Buzzatti, MD San Raffaele Scientific Institute Milan, Italy Mitral valve treatment in advanced heart failure: Repair, Replacement, MitraClip Nicola Buzzatti, MD San Raffaele Scientific Institute Milan, Italy Disclosures I have nothing to disclose FMR: a ventricular

More information

The Influence of Left Ventricular Ejection Fraction on the Effectiveness of Cardiac Resynchronization Therapy

The Influence of Left Ventricular Ejection Fraction on the Effectiveness of Cardiac Resynchronization Therapy Journal of the American College of Cardiology Vol. 61, No. 9, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.051

More information

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL DISCLOSURES I WILL BE DISCUSSING OFF-LABEL USAGE OF DEVICES RELATED TO TMVR OBJECTIVES

More information

Cardiac resynchronization therapy for mild-to-moderate heart failure

Cardiac resynchronization therapy for mild-to-moderate heart failure For reprint orders, please contact reprints@expert-reviews.com Cardiac resynchronization therapy for mild-to-moderate heart failure Expert Rev. Med. Devices 8(3), 313 317 (2011) Haran Burri Electrophysiology

More information

Provocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients

Provocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients Provocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients David E. Krummen, MD Associate Professor of Medicine University of California San Diego and VA San Diego Healthcare System

More information

Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT

Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT Heart Rhythm Society (May 11, 2012) Colin L. Doyle, BA,*

More information

Restrictive Cardiomyopathy

Restrictive Cardiomyopathy ESC Congress 2011, Paris Imaging Unusual Causes of Cardiomyopathy Restrictive Cardiomyopathy Kazuaki Tanabe, MD, PhD Professor of Medicine Chair, Division of Cardiology Izumo, Japan I Have No Disclosures

More information

Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction

Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction JC Eicher, G Laurent, O Barthez, A Mathé, G Bertaux, JE Wolf Heart Failure Treatment Unit, Rhythmology and

More information

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION Jamilah S AlRahimi Assistant Professor, KSU-HS Consultant Noninvasive Cardiology KFCC, MNGHA-WR Introduction LV function assessment in Heart Failure:

More information

Cardiac Resynchronization ICD Therapy: What is New?

Cardiac Resynchronization ICD Therapy: What is New? Cardiac Resynchronization ICD Therapy: What is New? Emile Daoud, MD Section Chief, Cardiac Electrophysiology Professor of Medicine The Ohio State University Normal Activation, Narrow QRS Synchrony Abnormal

More information

Heart Failure Overview. Dr Chris K Y Wong

Heart Failure Overview. Dr Chris K Y Wong Heart Failure Overview Dr Chris K Y Wong Heart Failure: A Growing, Global Health Issue Heart Failure 23 Million Afflicted Global Impact Worldwide ~23 million peopleworldwide afflicted with CHF 1 Exceeds

More information

Ramani GV et al. Mayo Clin Proc 2010;85:180-95

Ramani GV et al. Mayo Clin Proc 2010;85:180-95 THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation

More information

First question: Does CRT Work in AF?

First question: Does CRT Work in AF? CRT in AF Does it work and when to ablate AF versus AV node Maurizio Gasparini Chief EP and Pacing Unit Humanitas Research Hospital, Rozzano - Milano, Italy First question: Does CRT Work in AF? As any

More information